COLL

Rating neutralAI Memo

Collegium Pharmaceutical

As of 2026-05-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 revenue growth and cash generation stayed solid • 2026-05-07

Expected move: +38%

Biggest risk

The stock still has to digest integration risk, incremental leverage and contingent payments, and the usual pharma risks around competition, reimbursement, patent defense, and litigation; low analyst coverage means there is limited external validation.

Invalidation

Break below $26 or thesis failure.

What would change my mind?

Q1 showed solid top-line growth, JORNAY PM momentum, durable pain-portfolio revenue, strong cash generation, and an accretive AZSTARYS acquisition that should deepen the ADHD franchise and extend the revenue base.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-29

Base target

$42

p=50%

Bull target

$58

p=25%

Bear target

$26

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

AZSTARYS integration could extend the revenue base
Q1 showed solid top-line growth, JORNAY PM momentum, durable pain-portfolio revenue, strong cash generation, and an accretive AZSTARYS acquisition that should deepen the ADHD franchise and extend the revenue base.
The packet's median analyst target is $53.83 versus a $33.37 anchor price, which implies upside, but the analyst count is unavailable and the target set may be thin or stale, so treat it as a directional reference rather than a firm consensus.

BearKey bullets

AZSTARYS integration and ramp could underdeliver, especially with about $300M of delayed-draw term-loan funding and up to $135M of contingent milestones [#IR-2026-05-12].
Commercial performance still depends on prescription growth, payer access, and pricing in the ADHD and pain franchises [#10-K-2026-02-26].
If JORNAY PM or the pain portfolio slows, the updated 2026 outlook could prove too optimistic [#IR-2026-05-12].

WatchKey bullets

Q1 revenue growth and cash generation stayed solid

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $42 (p=50%)

Bull/Bear spread: +90% / -15%

Vs latest close: Bull +90% · Base +38% · Bear -15%

Scenario probabilities

Bull Target: $58 (p=25%)Base Target: $42 (p=50%)Bear Target: $26 (p=25%)

Commentary

Primary-source tone is constructive because Q1 showed growth, cash generation, and an accretive AZSTARYS close, but the packet still has low coverage, no social signal, and no analyst revision set, so this stays a cautious monitoring view rather than a high-conviction bull case.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

AZSTARYS integration could extend the revenue base

Scenarios

Bull Target (Scenario probability)

$58 / p=25% prob

Base Target (Scenario probability)

$42 / p=50% prob

Bear Target (Scenario probability)

$26 / p=25% prob

Price $30 as of 2026-06-02

Nearest Scenario: Bear (∆ 15%)

Targets vs latest close: Bull +90% · Base +38% · Bear -15%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Q1 revenue growth and cash generation stayed solid
Q1 2026 revenue rose 9% to $193.5M, JORNAY PM grew 36%, pain portfolio revenue grew 4%, cash from operations was $57.1M, and the company ended with $421.8M in cash, cash equivalents, and marketable securities; the 10-Q also disclosed the AZSTARYS purchase agreement and its cash/term-loan funding plan. [#IR-2026-05-07][#10Q-2026-05-07]
Prob 80.00% • Move 3.00% • Priced-in 75.00%
EVENT2026-05-12
AZSTARYS close and guidance raise added near-term upside
Collegium completed the AZSTARYS acquisition on May 12 and raised 2026 guidance to $865M-$895M in product revenues and $475M-$500M in adjusted EBITDA; AZSTARYS is expected to add $60M-$70M of 2H26 net revenue. [#IR-2026-05-12]
Prob 70.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

AZSTARYS integration could extend the revenue base
2027-05-12
Management says AZSTARYS should extend the revenue base into the late 2030s, with six Orange Book-listed patents lasting mostly until December 2037 and annual run-rate synergies expected to exceed $50M within 12 months, so execution of the integration and ramp is the key long-duration monitor. [#IR-2026-05-12]
Prob 55% • Move 9% • Priced-in 45%

Risks

AZSTARYS integration and ramp could underdeliver, especially with about $300M of delayed-draw term-loan funding and up to $135M of contingent milestones [#IR-2026-05-12].
Commercial performance still depends on prescription growth, payer access, and pricing in the ADHD and pain franchises [#10-K-2026-02-26].
If JORNAY PM or the pain portfolio slows, the updated 2026 outlook could prove too optimistic [#IR-2026-05-12].
Patent, litigation, and regulatory risk remain material for a commercial pharma portfolio [#10-K-2026-02-26].

Peers

Symbol	Summary
MNKD	Commercial-stage specialty pharma of comparable size; useful for judging durable prescription revenue and execution, though the therapeutic mix is different and the peer is only loosely comparable.
CRVS	Same-sector smaller-cap biotech with a similar market value but much earlier commercial maturity; mostly a sentiment and valuation comparator, not an operating comp.
EYPT	Similar-sized biopharma, but more R&D/launch dependent and less directly comparable to Collegium's cash-generative specialty-pharma model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-29

Loading AI feed…

Symbol

Summary

MNKD

Commercial-stage specialty pharma of comparable size; useful for judging durable prescription revenue and execution, though the therapeutic mix is different and the peer is only loosely comparable.

CRVS

Same-sector smaller-cap biotech with a similar market value but much earlier commercial maturity; mostly a sentiment and valuation comparator, not an operating comp.

EYPT

Similar-sized biopharma, but more R&D/launch dependent and less directly comparable to Collegium's cash-generative specialty-pharma model.